Sedation of Ventilated Traumatic Brain Injury Patients With Midazolam Alone Versus Combination With Dexmedetomidine or Magnesium Sulfate; Monitored by Ultrasonograghic Optic Nerve Sheath Diameter

A

Assiut University

Status and phase

Not yet enrolling
Phase 3

Conditions

TBI (Traumatic Brain Injury)

Treatments

Drug: dexmedetomidine
Radiation: Ultrasonograghic optic nerve sheath diameter US-ONSD
Drug: magnesium sulfate
Drug: midazolam

Study type

Interventional

Funder types

Other

Identifiers

NCT05340803
ONSD for TBI patients

Details and patient eligibility

About

In TBI, there is a strong correlation between increased ICP and bad outcome. So, appropriate monitoring can be the gold standard in management of TBI. ICP can be measured by invasive and noninvasive methds. One of these noninvasive methods is bedside measurement of optic nerve sheath diameter (ONSD) by ocular ultrasonography

Full description

In the previous few years, agreat evidence has established for efficiency of dexmedetomidine (DEX) in management of TBI. Dexmedetomidine is a highly selective alpha-2 receptor agonist, its major sympatholytic and sedative actions are mediated primarily via reduced transmission in the locus coeruleus which is a part of the reticular activating system. It provides excellent sedation without respiratory depression, ease of arousability, and need not be stopped during weaning the patient from mechanical ventilation or for neurological assessment. It suits as an ideal sedative agent for patients with TBI. DEX has been shown to reduce cerebral ischemia/ reperfusion injury by suppressing inflammation, activating the anti-apoptotic signaling pathways, and inhibiting neuronal autophagy. Animal studies have shown that alpha-2 agonists are neuroprotective in craniocerebral and subarachnoid injuries but this has not been definitively shown in humans . The efficacy of DEX for sedation in intubated ICU patients is well established; however, its use in patients with TBI has not been comprehensively described . Magnesium has shown great promise as a potential therapeutic agent in TBI during animal experiments . Magnesium is essential for the maintenance of cell membrane integrity, the stabilisation of genetic material and for a number of fundamental enzymatic reactions such as glycolysis, oxidative phosphorylation and protein synthesis, it is also known to act presynaptically to inhibit the release of excitatory amino acids, and be a non-competitive inhibitor of the voltage-gated N-methyl-D-aspartate (NMDA) receptor, an important link in the excitotoxic phase of secondary brain injury. As a consequence, magnesium's role in TBI has been of great interest to researchers.

Enrollment

108 estimated patients

Sex

All

Ages

18 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Middle age patients ( 18- 45 years old).
  2. Sever TBI (GCS < 8 and in need for mechanical ventilation).
  3. Stable hemodynamics

Exclusion criteria

  1. Age: younger than 18 or older than 45 years old.
  2. Mild and moderate TBI (GCS > 8).
  3. Shocked and hypoxic patients.
  4. Contraindications to dexmedetomidine as sever hypotension (mean arterial blood pressure < 60 mmHg), sever bradycardia (heart rate < 45 beat/min), and AV block in the group that will be sedated by midazolam and dexmedetomidine (group B).
  5. Adverse effects of dexmedetomidine in group B and need to stop it as sever hypotension (mean arterial blood pressure < 60 mmHg) , sever bradycardia (heart rate < 45 beat/min), and atrial fibrillation.
  6. Contraindications to magnesium sulfate as heart block, myocardial damage, hypermagnesemia and renal failure in the group that will be sedated by midazolam and magnesium sulfate (group C).
  7. Manifestations of magensium toxicity in group C and need to stop infusion if urine output < 80 mL in 4 hours, deep tendon reflexes are absent or serum magnesium level > 3.5 mmol/L .

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

108 participants in 3 patient groups

Group A
Active Comparator group
Description:
Sedation by midazolam alone
Treatment:
Drug: midazolam
Radiation: Ultrasonograghic optic nerve sheath diameter US-ONSD
Group B
Active Comparator group
Description:
Sedation by midazolam and dexmedetomidine during the first 24 hours
Treatment:
Drug: midazolam
Radiation: Ultrasonograghic optic nerve sheath diameter US-ONSD
Drug: dexmedetomidine
Group C
Active Comparator group
Description:
Sedation by midazolam and magnesium sulfate during the first 24 hours
Treatment:
Drug: magnesium sulfate
Drug: midazolam
Radiation: Ultrasonograghic optic nerve sheath diameter US-ONSD

Trial contacts and locations

0

Loading...

Central trial contact

Alshymaa Hassan Mohammed, Master

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems